Myriad Genetics Announces Senior Leadership Transition

Core Viewpoint - Myriad Genetics, Inc. has appointed Sam Raha as the new CEO effective April 30, 2025, succeeding Paul J. Diaz, who will transition to a consulting role for one year [1][2]. Leadership Transition - Sam Raha, currently the COO, has been recognized for his role in shaping the company's long-term growth strategy since joining in December 2023 [2]. - The Board of Directors expressed confidence in Raha's leadership, emphasizing his extensive background in the diagnostics industry [2]. - Paul J. Diaz has been credited with transforming Myriad over the past four-and-a-half years, enhancing its brand and operational capacity [2][3]. Future Strategy - Raha aims to accelerate the company's growth and profitability through innovation and a comprehensive portfolio, while focusing on patient needs and healthcare providers [2]. - The company is also in the process of searching for a new Chief Commercial Officer (CCO) following the promotion of Mark S. Verratti to COO [1][2]. Company Background - Myriad Genetics specializes in molecular diagnostics testing and precision medicine, aiming to improve patient care and reduce healthcare costs through its molecular tests [4].